Company Overview of Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling pharmaceutical products. It focuses on central nervous system, gastrointestinal, general products, renal diseases, and human genetic therapies. The company offers ADDERALL and ADDERALL XR for attention deficit hyperactivity disorder (ADHD); REMINYL for Alzheimer's; and CARBATROL for epilepsy. It also develops a range of treatments for ADHD to treat children, adolescents, and adults, as well as researches on non-scheduled compounds. The company markets its products to defined customer groups, such as specialist doctors. It has sales and marketing infrastructure with a portfolio of products targeting the U...
725 Chesterbrook Boulevard
Wayne, PA 19087
Founded in 2004
Key Executives for Shire Pharmaceuticals, Inc.
Shire Pharmaceuticals, Inc. does not have any Key Executives recorded.
Shire Pharmaceuticals, Inc. Key Developments
Shire Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 03:45 PM
Oct 7 13
Shire Pharmaceuticals, Inc. Presents at 19th Annual BIO-Europe International Partnering Conference, Nov-04-2013 03:45 PM. Venue: Messe Wien Exhibition and Congress Center, Vienna, Austria. Speakers: Charlie Alexander, Senior Director, Business Development.
Massachusetts Institute of Technology Accuses Shire Pharmaceuticals and Shire Regenerative Medicine's Dermagraft of Infringing Skin Growth Patents
Jan 14 13
Shire Pharmaceuticals, Inc. and its Advanced BioHealing, Inc. (Shire Regenerative Medicine) are facing civil charges of violating patents held by the Massachusetts Institute of Technology and Children's Medical Center Corporation (CCMC) in marketing a diabetic foot ulcer treatment. The case, filed in Massachusetts district court Jan. 4, involves three 1998 patents describing techniques to attach living human cells to a mesh that can then be implanted to regrow skin tissue. Dermagraft consists of a bioabsorbable mesh scaffold that can be seeded with human fibroblast cells, which grow on the scaffold, secreting collagen and other substances. The result is a three-dimensional skin substitute made of living cells, according to the complaint. The FDA approved the device in 2001 to treat full-thickness diabetic foot ulcers. MIT and CCMC initially licensed the technologies to Advanced Tissue Sciences, which obtained Dermagraft's approval and launched the product in the market. When the company went out of business in 2006, Dermagraft was sold to Advanced BioHealing. Shire acquired Advanced BioHealing in 2011, renaming the division Shire Regenerative Medicine the following year. MIT attempted to discuss the licensing arrangement with Shire after that purchase, but received no response, according to the lawsuit. The complaint charges Shire with three counts of knowingly infringing on the MIT and CCMC patents. The plaintiffs which have requested a jury trial are seeking damages, attorney fees, and unspecified further relief.
Shire Pharmaceuticals, Inc. Presents at Science, Partner, and Investment Forum 2012, May-21-2012 10:10 AM
May 17 12
Shire Pharmaceuticals, Inc. Presents at Science, Partner, and Investment Forum 2012, May-21-2012 10:10 AM. Venue: Palm Beach County Convention Center, West Palm Beach, Florida, United States. Speakers: Gwen Melincoff, Senior Vice President, Business Development.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|